Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1379P - Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A

Date

16 Sep 2021

Session

ePoster Display

Presenters

Daniel Catenacci

Citation

Annals of Oncology (2021) 32 (suppl_5): S1040-S1075. 10.1016/annonc/annonc708

Authors

D.V. Catenacci1, H. Park2, B.Y. Shim3, S.T. Kim4, D. Oh5, A. Spira6, S. Ulahannan7, E.J. Avery8, P.M. Boland9, J. Chao10, H.C. Chung11, F. Gardner12, S.J. Klempner13, K. Lee14, S.C. Oh15, J. Peguero16, M.B. Sonbol17, J. Sun18, M.K. Rosales19, Y. Kang20

Author affiliations

  • 1 Medicine, The University of Chicago Medical Centre, 60653 - Chicago/US
  • 2 Department Of Medicine, Washington University School of Medicine, 63110 - St. Louis/US
  • 3 Medical Oncology, The Catholic University of Korea St. Vincent's Hospital, 16247 - Suwon/KR
  • 4 Hematology And Oncology, Samsung Medical Center, Seoul/KR
  • 5 Internal Medicine, Seoul National University, Seoul/KR
  • 6 N/a, Virginia Cancer Specialists Research Institute, Fairfax/US
  • 7 Faculty Of Hematology And Oncology, Sarah Cannon Research Institute, Nashville, TN, USA; University of Oklahoma Health Sciences Center - Stephenson Cancer Center, Oklahoma City/US
  • 8 Hematology And Oncology, Nebraska Hematology-Oncology, Lincoln/US
  • 9 Medical Oncology, Rutgers Cancer Institute of New Jersey, 08903 - New Brunswick/US
  • 10 Department Of Medical Oncology & Therapeutics Research, City of Hope, 91010 - Duarte/US
  • 11 Medical Oncology Dept, Yonsei University, 03722 - Seoul/KR
  • 12 General Hematology, Florida Cancer Specialists, 33914 - Cape Coral/US
  • 13 Mass General Hospital Cancer Center, Massachusetts General Hospital, 02114 - Boston/US
  • 14 Hematology And Oncology, Seoul National University Bundang Hospital, Gyeonggi-do/KR
  • 15 Oncology, Korea University Guro Hospital, Seoul/KR
  • 16 Medical Oncology, Oncology Consultants, 77030 - Houston/US
  • 17 Internal Medicine Department, Mayo Clinic Cancer Center, 85054 - Phoenix/US
  • 18 Biostatistics, MacroGenics, Inc., Rockville/US
  • 19 Clinical Department, MacroGenics, Inc., 20850 - Rockville/US
  • 20 Department Of Oncology, Asan Medical Center, Seoul/KR
More

Abstract 1379P

Background

The monoclonal antibody (mAb) trastuzumab plus chemotherapy has been 1st-line standard of care in HER2+ metastatic GEA for a decade. M is an investigational (in GEA) anti-HER2 mAb engineered to confer enhanced Fc dependent antitumor activity across all Fc region gamma receptor genotypes. M may potentiate innate immunity (i.e. antibody-dependent cellular cytotoxicity) and adaptive immunity (i.e. anti-HER2–directed T-cell responsiveness). R, an investigational humanized IgG4 mAb, binds to PD-1 and blocks its interaction with PD-L1/2.

Methods

MAHOGANY is a 2-cohort study in unresectable metastatic/locally advanced GEA. Cohort A (100 pt single arm) will determine safety/efficacy of Q3W M 15 mg/kg plus R 375 mg in HER2 3+, PD-L1+ (CPS ≥1) and non–microsatellite instability high pts. Primary endpoint of Cohort A is centrally-reviewed overall response rate (ORR); Investigator-assessed ORR is supportive.

Results

As of 16 April 2021, 43 pts were enrolled, with median exposure of 4.2 months and median duration of follow-up of 4.6 months. Safety data are available on 43; efficacy data are available on 43 with baseline scan for response assessment by the investigators. Of these 43, 37 have reached first tumor reassessment, with 1 confirmed complete response, 11 confirmed partial responses, 1 unconfirmed complete response, 11 unconfirmed partial responses, 7 stable disease, and 6 progressive disease (5 PD at first scan, 1 clinical PD). Tumor shrinkage was seen in 30/35 pts (85.7%) with at least 1 post-baseline target lesion measurement. The most common treatment-related adverse events were infusion related reaction (8/43, 18.6%), diarrhea and fatigue (6/43, 14% each). Grade 3 treatment-related events were singularly reported with no ≥ Grade 3 infusion related reaction or diarrhea. Regarding immune-related events, 1 pt discontinued due to renal dysfunction possibly related to M+R, 4 had hypothyroidism and 1 had immune-related renal dysfunction.

Conclusions

This first report of MAHOGANY Cohort A of M plus R suggests the combination is well tolerated. The updated efficacy data including centrally-reviewed scans will be available at presentation.

Clinical trial identification

NCT04082364.

Editorial acknowledgement

Legal entity responsible for the study

MacroGenics, Inc.

Funding

MacroGenics, Inc.

Disclosure

D.V. Catenacci: Financial Interests, Personal, Other, Honoraria: Amgen; Astellas Pharma; Bristol-Myers Squibb; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; Gritsone Oncology; Guardant Health; Lilly; Merck; Seattle Genetics; Taiho Pharmaceutical; Tempus; Daichii Sankyo; Basilea; QED; Arcus; Ono; Archer; Natera; Financial Interests, Personal, Advisory Role: Amgen; Astellas Pharma; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; Seattle Genetics; Taiho Pharmaceutical; Daichii Sankyo; Ono; Arcus; Basilea; QED; Archer; Natera; Financial Interests, Personal, Speaker’s Bureau: Foundation Medicine; Genentech/Roche; Guardant Health; Lilly; Merck; Daichii Sankyo; Tempus. H. Park: Financial Interests, Institutional, Principal Investigator: Ambrx; Financial Interests, Institutional, Principal Investigator: Amgen; Financial Interests, Institutional, Principal Investigator: Aprea; Financial Interests, Institutional, Principal Investigator: Array; Financial Interests, Institutional, Principal Investigator: Bayer; Financial Interests, Institutional, Principal Investigator: BeiGene; Financial Interests, Institutional, Principal Investigator: BJ Bioscience; Financial Interests, Institutional, Principal Investigator: Bristol-Myers Squibb; Financial Interests, Institutional, Principal Investigator: Daiichi Pharmaceutical; Financial Interests, Institutional, Principal Investigator: Eli Lilly; Financial Interests, Institutional, Principal Investigator: Elicio Therapeutics; Financial Interests, Institutional, Principal Investigator: EMD Serono; Financial Interests, Institutional, Principal Investigator: Genentech; Financial Interests, Institutional, Principal Investigator: Gilead Sciences; Financial Interests, Institutional, Principal Investigator: GlaxoSmithKline; Financial Interests, Institutional, Principal Investigator: Gossamer Bio; Financial Interests, Institutional, Principal Investigator: Hoffman-LaRoche; Financial Interests, Institutional, Principal Investigator: Hutchison MediPharma; Financial Interests, Institutional, Principal Investigator: ImmuneOncia Therapeutics; Financial Interests, Institutional, Principal Investigator: Incyte; Financial Interests, Institutional, Principal Investigator: Jounce Therapeutics; Financial Interests, Institutional, Principal Investigator: Mabspace Biosciences; Financial Interests, Institutional, Principal Investigator: MacroGenics, Inc.; Financial Interests, Institutional, Principal Investigator: Medimmune; Financial Interests, Institutional, Principal Investigator: Medivation; Financial Interests, Institutional, Principal Investigator: MERCK; Financial Interests, Institutional, Principal Investigator: Millennium; Financial Interests, Institutional, Principal Investigator: Mirati Therapeutics; Financial Interests, Institutional, Principal Investigator: Novartis Pharmaceuticals; Financial Interests, Institutional, Principal Investigator: Oncologie; Financial Interests, Institutional, Principal Investigator: Pfizer; Financial Interests, Institutional, Principal Investigator: PsiOxus; Financial Interests, Institutional, Principal Investigator: Puma Biotechnology; Financial Interests, Institutional, Principal Investigator: Regeneron Pharmaceuticals; Financial Interests, Institutional, Principal Investigator: Seattle Genetics; Financial Interests, Institutional, Principal Investigator: Synermore Biologics; Financial Interests, Institutional, Principal Investigator: Taiho Pharmaceutical; Financial Interests, Institutional, Principal Investigator: TopAlliance Biosciences; Financial Interests, Institutional, Principal Investigator: Turning Point Therapeutics; Financial Interests, Institutional, Principal Investigator: Vedanta Biosciences; Financial Interests, Institutional, Principal Investigator: Vertex Pharmaceuticals; Financial Interests, Institutional, Principal Investigator: Xencor Inc. D. Oh: Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Genentech/Roche; Financial Interests, Personal, Advisory Board: Merck Serono; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Taiho; Financial Interests, Personal, Advisory Board: ASLAN; Financial Interests, Personal, Advisory Board: Halozyme; Financial Interests, Personal, Advisory Board: Zymeworks; Financial Interests, Personal, Advisory Board: BMS/Celgene; Financial Interests, Personal, Advisory Board: BeiGene; Financial Interests, Personal, Advisory Board: Basilea; Financial Interests, Personal, Advisory Board: Turning Point; Financial Interests, Institutional, Research Grant: AstraZeneca; Financial Interests, Institutional, Research Grant: Novartis; Financial Interests, Institutional, Research Grant: Array; Financial Interests, Institutional, Research Grant: Eli Lilly; Financial Interests, Institutional, Research Grant: Servier; Financial Interests, Institutional, Research Grant: BeiGene; Financial Interests, Institutional, Research Grant: MSD; Financial Interests, Institutional, Research Grant: Handok. A. Spira: Financial Interests, Personal, Stocks/Shares: Lilly; Financial Interests, Personal, Other, Honoraria: Amgen; Financial Interests, Personal, Other, Honoraria: AstraZeneca/MedImmune; Financial Interests, Personal, Other, Honoraria: CytomX Therapeutics; Financial Interests, Personal, Other, Honoraria: Merck; Financial Interests, Personal, Other, Honoraria: Takeda; Financial Interests, Personal, Advisory Role, Research funding: Amgen; Financial Interests, Institutional, Advisory Role, Research funding: Array BioPharma; Financial Interests, Institutional, Advisory Role, Research funding: AstraZeneca/MedImmune; Financial Interests, Personal, Advisory Role, Research funding: Incyte; Financial Interests, Personal, Advisory Role, Research funding: Novartis; Financial Interests, Institutional, Other, Research funding: AbbVie; Financial Interests, Institutional, Other, Research funding: ADC Therapeutics; Financial Interests, Institutional, Other, Research funding: Amgen; Financial Interests, Institutional, Other, Research funding: Arch Therapeutics; Financial Interests, Institutional, Other, Research funding: Astellas Pharma; Financial Interests, Institutional, Other, Research funding: Astex Pharmaceuticals; Financial Interests, Institutional, Other, Research funding: AstraZeneca; Financial Interests, Institutional, Other, Research funding: Boehringer Ingelheim; Financial Interests, Institutional, Other, Research funding: Bristol-Myers Squibb; Financial Interests, Institutional, Other, Research funding: CytomX Therapeutics; Financial Interests, Institutional, Other, Research funding: Daiichi Sankyo; Financial Interests, Institutional, Other, Research funding: Gritstone Oncology; Financial Interests, Institutional, Other, Research funding: Ignyta; Financial Interests, Institutional, Other, Research funding: Incyte; Financial Interests, Institutional, Other, Research funding: LAM Therapeutics; Financial Interests, Institutional, Other, Research funding: Loxo; Financial Interests, Institutional, Other, Research funding: MacroGenics; Financial Interests, Institutional, Other, Research funding: MedImmune; Financial Interests, Institutional, Other, Research funding: Newlink Genetics; Financial Interests, Institutional, Other, Research funding: Novartis; Financial Interests, Institutional, Other, Research funding: Plexxikon; Financial Interests, Institutional, Other, Research funding: Roche; Financial Interests, Institutional, Other, Research funding: Takeda; Financial Interests, Institutional, Other, Research funding: Trovagene. S. Ulahannan: Financial Interests, Personal, Advisory Board: Array; Financial Interests, Personal, Advisory Board: Incyte; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Syros; Financial Interests, Personal, Advisory Board: Eisai; Financial Interests, Institutional, Principal Investigator: AbbVie, Inc.; Financial Interests, Institutional, Principal Investigator: ArQule, Inc.; Financial Interests, Institutional, Principal Investigator: AstraZeneca; Financial Interests, Institutional, Principal Investigator: Atreca; Financial Interests, Institutional, Principal Investigator: Boehringer Ingelheim; Financial Interests, Institutional, Principal Investigator: Bristol-Myers Squibb; Financial Interests, Institutional, Principal Investigator: Celgene Corporation; Financial Interests, Institutional, Principal Investigator: Ciclomed LLC; Financial Interests, Institutional, Principal Investigator: Evelo Biosciences, Inc.; Financial Interests, Institutional, Principal Investigator: G1 Therapeutics, Inc.; Financial Interests, Institutional, Principal Investigator: GlaxoSmithKline; Financial Interests, Institutional, Principal Investigator: IGM biosciences; Financial Interests, Institutional, Principal Investigator: Incyte; Financial Interests, Institutional, Principal Investigator: Isofol; Financial Interests, Institutional, Principal Investigator: Klus Pharma, Inc.; Financial Interests, Institutional, Principal Investigator: MacroGenics, Inc.; Financial Interests, Institutional, Principal Investigator: Merck Co. Inc.; Financial Interests, Institutional, Principal Investigator: Mersana Therapeutics; Financial Interests, Institutional, Principal Investigator: OncoMed Pharmaceuticals, Inc.; Financial Interests, Institutional, Principal Investigator: Pfizer; Financial Interests, Institutional, Principal Investigator: Regeneron, Inc.; Financial Interests, Institutional, Principal Investigator: Revolution Medicines, Inc.; Financial Interests, Institutional, Principal Investigator: Synermore Biologics Co; Financial Interests, Institutional, Principal Investigator: Takeda; Financial Interests, Institutional, Principal Investigator: Tarveda Therapeutics; Financial Interests, Institutional, Principal Investigator: Tesaro; Financial Interests, Institutional, Principal Investigator: Tempest; Financial Interests, Institutional, Principal Investigator: Vigeo Therapeutics, Inc. E.J. Avery: Financial Interests, Personal, Advisory Role: AstraZeneca; Financial Interests, Institutional, Funding: Lilly; Financial Interests, Personal, Other, Travel, accommodations, expenses: AstraZeneca. P.M. Boland: Financial Interests, Personal, Advisory Role: Bayer; Financial Interests, Institutional, Funding: Boehringer Ingelheim; Financial Interests, Institutional, Funding: Merck; Financial Interests, Institutional, Funding: Bayer; Financial Interests, Institutional, Funding: Boston Biomedical; Financial Interests, Institutional, Funding: Ipsen; Financial Interests, Institutional, Funding: Athenex; Financial Interests, Institutional, Funding: AbbVie. J. Chao: Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: Astellas; Other, Personal, Other, Consulting: AstraZeneca; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Other, Personal, Other, Consulting: Lilly; Financial Interests, Personal, Advisory Board: MacroGenics, Inc.; Financial Interests, Personal, Invited Speaker: Merck; Financial Interests, Personal, Advisory Board: Merck; Other, Personal, Other, Consulting: Ono Pharmaceuticals; Other, Personal, Other, Consulting: Roche; Financial Interests, Personal, Advisory Board: Turning Point Therapeutics; Financial Interests, Personal, Advisory Board: Brooklyn Immunotherapeutics; Financial Interests, Institutional, Funding: Merck. H.C. Chung: Financial Interests, Institutional, Research Grant: Lilly; Financial Interests, Institutional, Research Grant: GSK; Financial Interests, Institutional, Research Grant: MSD; Financial Interests, Institutional, Research Grant: Merck-Serono; Financial Interests, Institutional, Research Grant: BMS/Ono; Financial Interests, Institutional, Research Grant: Taiho; Financial Interests, Institutional, Research Grant: Amgen; Financial Interests, Institutional, Research Grant: Beigene; Financial Interests, Institutional, Research Grant: Incyte; Financial Interests, Institutional, Research Grant: Zymework; Financial Interests, Personal, Other, Honoraria: Merck-Serono; Financial Interests, Personal, Other, Honoraria: Lilly; Financial Interests, Personal, Advisory Role: Taiho; Financial Interests, Personal, Advisory Role: Celltrion; Financial Interests, Personal, Advisory Role: MSD; Financial Interests, Personal, Advisory Role: Lilly; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Merck-Serono; Financial Interests, Personal, Advisory Role: Gloria; Financial Interests, Personal, Advisory Role: Beigene; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Advisory Role: Zymework. F. Gardner: Financial Interests, Personal, Advisory Role: Oasis 360; Financial Interests, Personal, Advisory Role: bioTheranostics; Financial Interests, Personal, Advisory Role: Janssen; Financial Interests, Personal, Leadership Role: Florida Cancer Specialists; Financial Interests, Personal, Speaker’s Bureau: Epizyme; Financial Interests, Personal, Speaker’s Bureau: Regeneron; Financial Interests, Personal, Speaker’s Bureau: Sanofi; Financial Interests, Personal, Speaker’s Bureau: Pfizer; Financial Interests, Institutional, Funding: Novartis Pharmaceuticals UK Ltd; Financial Interests, Institutional, Funding: Genentech; Financial Interests, Institutional, Funding: Lilly; Financial Interests, Institutional, Funding: Astellas Pharma; Financial Interests, Institutional, Funding: MacroGenics; Financial Interests, Institutional, Funding: Pharmacyclics. S.J. Klempner: Financial Interests, Personal, Advisory Board, Stomach Cancer Advisory Board: Eli Lilly; Financial Interests, Personal, Advisory Board, Stomach Cancer Advisory Board: Merck; Financial Interests, Personal, Advisory Board, Stomach Cancer Advisory Board: Bristol Myers Squibb; Financial Interests, Personal, Advisory Board, Stomach Cancer Advisory Board: Astellas; Financial Interests, Personal, Advisory Board, Stomach Cancer Advisory Board: Daiichi Sankyo; Financial Interests, Personal, Advisory Board, One time advisory board: Natera; Financial Interests, Personal, Advisory Board, Stomach Cancer Advisory Board: Pieris; Financial Interests, Personal, Stocks/Shares: Turning Point Therapeutics; Non-Financial Interests, Personal, Principal Investigator: Leap Therapeutics; Financial Interests, Personal and Institutional, Principal Investigator: Astellas; Financial Interests, Personal and Institutional, Advisory Board, MacroGenics, Inc.: Astellas; Non-Financial Interests, Institutional, Principal Investigator: MacroGenics, Inc. K. Lee: Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: Daiichi Sankyo; Financial Interests, Personal, Advisory Role: ISU ABXIS; Financial Interests, Institutional, Principal Investigator: ABLBIO; Financial Interests, Institutional, Principal Investigator: ALX Oncology; Financial Interests, Institutional, Principal Investigator: AstraZeneca; Financial Interests, Institutional, Principal Investigator: Beigene; Financial Interests, Institutional, Principal Investigator: Daiichi Sankyo; Financial Interests, Institutional, Principal Investigator: Five Prime Therapeutics; Financial Interests, Institutional, Principal Investigator: Genexine; Financial Interests, Institutional, Principal Investigator: Green Cross Corp.; Financial Interests, Institutional, Principal Investigator: LSK BioPharma; Financial Interests, Institutional, Principal Investigator: MacroGenics, Inc.; Financial Interests, Institutional, Principal Investigator: Merck KGaA; Financial Interests, Institutional, Principal Investigator: Merck Sharp & Dohme; Financial Interests, Institutional, Principal Investigator: Oncologie; Financial Interests, Institutional, Principal Investigator: Ono pharmaceutical; Financial Interests, Institutional, Principal Investigator: Pfizer; Financial Interests, Institutional, Principal Investigator: Pharmacyclics; Financial Interests, Institutional, Principal Investigator: Taiho Pharmaceutical; Financial Interests, Institutional, Principal Investigator: Y-BIOLOGICS; Financial Interests, Institutional, Principal Investigator: Zymeworks. J. Peguero: Financial Interests, Personal, Full or part-time Employment: Oncology Consultants; Financial Interests, Personal, Leadership Role: Oncology Consultants; Financial Interests, Personal, Stocks/Shares: Oncology Consultants; Financial Interests, Personal, Stocks/Shares: Zogen; Financial Interests, Personal, Other, Honoraria: Tempus; Financial Interests, Personal, Invited Speaker, Honoraria: Agendia; Financial Interests, Personal, Invited Speaker, Honoraria: Guardant Health; Financial Interests, Personal, Advisory Role: TerSera Therapeutics; Financial Interests, Personal, Speaker’s Bureau: Tempus; Financial Interests, Personal, Speaker’s Bureau: Agendia; Financial Interests, Personal, Speaker’s Bureau: Guardant Health; Financial Interests, Institutional, Principal Investigator: Immutep; Financial Interests, Institutional, Principal Investigator: GNE/Roche; Financial Interests, Institutional, Principal Investigator: Immatics; Financial Interests, Institutional, Principal Investigator: NovoCure; Financial Interests, Institutional, Principal Investigator: Amgen; Financial Interests, Institutional, Principal Investigator: EMD Serono; Financial Interests, Institutional, Principal Investigator: Loxo Oncology; Financial Interests, Institutional, Principal Investigator: Eli Lilly; Financial Interests, Institutional, Principal Investigator: Turning Point Therapeutics; Financial Interests, Institutional, Principal Investigator: Barvarian Nordic; Financial Interests, Institutional, Principal Investigator: IncMed; Financial Interests, Institutional, Principal Investigator: Immunity Bio (Altor); Financial Interests, Institutional, Principal Investigator: Incyte; Financial Interests, Institutional, Principal Investigator: AbbVie; Financial Interests, Institutional, Principal Investigator: MacroGenics; Financial Interests, Institutional, Principal Investigator: Dizal; Financial Interests, Institutional, Principal Investigator: BerGenBio; Financial Interests, Institutional, Principal Investigator: Epizyme; Financial Interests, Institutional, Principal Investigator: Astella; Financial Interests, Institutional, Principal Investigator: Janssen; Financial Interests, Institutional, Principal Investigator: Thrive Earlier Detection Corp; Financial Interests, Institutional, Principal Investigator: Boehringer Ingelheim; Financial Interests, Institutional, Principal Investigator: TerSera; Financial Interests, Institutional, Principal Investigator: Natera; Financial Interests, Institutional, Principal Investigator: Ipsen Bioscience; Financial Interests, Institutional, Principal Investigator: Mitati Therapeutics; Financial Interests, Institutional, Principal Investigator: Calithera Biosciences; Financial Interests, Institutional, Principal Investigator: Effector Therapeutics, Inc.; Financial Interests, Institutional, Principal Investigator: KeChow Pharmaceuticals, Inc.; Financial Interests, Institutional, Principal Investigator: Sermonix Pharmaceuticals; Financial Interests, Personal, Other, Travel/accomodations/expenses: Tempus; Financial Interests, Personal, Other, Travel/accomodations/expenses: Agendia; Financial Interests, Personal, Other, Travel/accomodations/expenses: Guardant Health. J. Sun: Financial Interests, Personal, Full or part-time Employment: MacroGenics, Inc.; Financial Interests, Personal, Stocks/Shares: MacroGenics, Inc. M.K. Rosales: Financial Interests, Personal, Full or part-time Employment: MacroGenics, Inc.; Financial Interests, Personal, Full or part-time Employment: MacroGenics, Inc. Y. Kang: Financial Interests, Personal, Advisory Role: ALX Oncology; Financial Interests, Personal, Advisory Role: Zymeworks; Financial Interests, Personal, Advisory Role: Amgen; Financial Interests, Personal, Advisory Role: Novartis; Financial Interests, Personal, Advisory Role: MacroGenics, Inc.; Financial Interests, Personal, Advisory Role: Daehwa; Financial Interests, Personal, Advisory Role: Blueprint; Financial Interests, Personal, Advisory Role: Surface Oncology; Financial Interests, Personal, Advisory Role: BMS; Financial Interests, Personal, Advisory Role: Merck MSD. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings